A unit of Chinese contract drugmaker Wuxi Biologics has experienced overwhelming demand for its initial public offering (IPO) in Hong Kong, closing its order book early and potentially pricing the deal at the top of its marketed range, according to sources familiar with the matter. This is a remarkable occurrence in a year that has seen a turbulent market for listings in Hong … [Read more...] about Wuxi XDC Cayman: Strong Demand for IPO in Hong Kong
Footer
